Skip to main content
Article thumbnail
Location of Repository

The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size

By Sae Byeol Choi, Kyung Sik Kim, Young Nyun Park, Jin Sub Choi, Woo Jung Lee, Jinsil Seong, Kwang-Hyub Han and Jong Tae Lee


In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study

Topics: Original Article
Publisher: The Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1987). A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer
  2. (1989). Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery
  3. (1992). Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.
  4. (2007). Combined therapy of transcatheter arterial chemoembolization and three dimensional-dimensional conformal radiotherapy for hepatocellular carcinoma.
  5. (1999). Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.
  6. (2003). Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.
  7. (1993). Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer
  8. (2001). Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.
  9. (2000). Estimating the world cancer246
  10. (1998). Hepatic resection for hepatocellular carcinoma--Japanese experience. Hepatogastroenterology
  11. (1990). Hepatic resection for hepatocellular carcinoma. Surgery
  12. (2000). Horng CF. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma.
  13. (1997). Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg
  14. (1995). Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg
  15. (2007). Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg
  16. Korean statistical information system. Annual report on the cause of death statistics. Available at:
  17. (2000). Liver Cancer Study Group of Japan: Stage. The general rules for the clinical and pathological study of primary liver cancer. 4th Ed. Tokyo: Kanahara and Co;
  18. (2005). Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int
  19. (1991). Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma. Cancer
  20. (2006). New indication for reduction surgery in patients with advanced hepatocellular carcinoma with major vascular involvement. World J Surg
  21. (2001). Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg
  22. (1999). Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas: retrospective analysis of 120 cases.
  23. (2006). Preoperative transcatheter arterial chemoembolization reduces longterm survival rate after hepatic resection for resectable hepatocellular carcinoma .
  24. (1997). Prognosis and prognostic factors in patients with hepatocellular carcinoma treated by transarterial chemoembolization.
  25. (2003). Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma.
  26. (1995). Pulmonary metastasis of hepatocellular carcinoma associated with transar-Efficacy of Preoperative Radiation Therapy and TACE
  27. (2004). Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg
  28. (1996). Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.
  29. (2000). Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg
  30. (2000). Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol
  31. (2001). The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.